One study, investigating the combination of MUC1-specific DC therapy in combination with MUC1-specific cytotoxic T lymphocyte ACT in 20 patients with advanced pancreatic cancer (APC) yielded a CR in one patient (5%), stable disease in 25% (5/20), a mean survival of 9.8 mo, and no grade 3–4 toxicity [113]. This evidence concerns the gene MUC1 and pancreatic neoplasm.